TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06264739

Intervention type: DRUG
Group type: OTHER
Intervention: esp Dexmedetomidine (dekstomid)
Description: After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.

Intervention type: DRUG
Group type: OTHER
Intervention: esp remifentanyl (ultiva)
Description: After anesthesia and surgical procedures, bilateral ESP block will be applied under ultrasonography guidance from the midline 3 cm lateral from the T10 level. After cleaning the area with povidone-iodine before the block, the T10 transverse protrusion will be determined using a linear ultrasound probe. Local anesthetic will be applied between the transverse process and the erector spinae muscle with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection with physiological saline without local anesthesia. After the location of the needle is confirmed, 20 ml of LA and saline mixture will be applied and the same process will be repeated in the contralateral side. Of the total 40 ml LA, 20 ml will consist of bupivacaine 0.5% (marcaine), 10 ml will consist of lidocaine 2% (aritmal), and 10 ml will consist of physiological saline.
Study: NCT04958499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bio-healthy Park
Description: Experimental group will receive the exercise program on bio-healthy machinery with a frequency of 2 sessions per week of 55 minutes for 8 weeks. Experimental group 1 will perform the intervention program using machinery designed for self-loading use. The machines used will be rider, low gemini, high gemini, walk, bottoms, flywheels circles, flywheels rotation, twin swing, surf, swing press and rowing. Intensity will be controlled by subjective perception of effort and heart rate (Polar 420). There will be a warm-up 8-10 minutes, a main part 40-45 minutes and a return to calm 5-10 minutes. The intervention programs will be developed by a graduate in Physical Activity and Sport Sciences. The load will be progressed every 2 weeks.
Study: NCT06410898

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Biopsy 5mm
Description: Disinfect the skin, inject local anesthesia ,insert the punch and extract the biopsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Biopsy 5mm
Description: Disinfect the skin, inject local anesthesia ,insert the punch and extract the biopsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Biopsy 5mm
Description: Disinfect the skin, inject local anesthesia ,insert the punch and extract the biopsy
Study: NCT04781166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm program
Description: 7 online modules designed to teach cognitive behavioral skills

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calm program
Description: 7 online modules designed to teach cognitive behavioral skills
Study: NCT05880966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Fitness
Description: Six month, thrice weekly functional fitness sessions will include a warm-up (15 minutes), skill or strength work (30 minutes) and a cool down (15 minutes)
Study: NCT05103371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiment: Millie prevention program, adolescents and active parents
Description: Prevention program: Millie, with the participation of adolescents and parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experiment: Millie prevention program, adolescents only
Description: Prevention program: Millie, with the participation of adolescents only, no parental involvement in the program
Study: NCT05842772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shared decision making intervention for patients with kidney failure when planning end-of-life care
Description: Testing a shared decision making intervention and a patient decision aid for patients with kidney failure, their relatives, and the health professionals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision making intervention for patients with kidney failure when planning end-of-life care
Description: Testing a shared decision making intervention and a patient decision aid for patients with kidney failure, their relatives, and the health professionals.
Study: NCT04830930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381
Description: single-dose, oral administration of CKD-381 1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381
Description: single-dose, oral administration of CKD-381 1 tablet
Study: NCT05304052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation classes
Description: The mindful awareness practices (MAPS) intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA, but takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life (as compared to the focus on stress and stress reduction in mindfulness-based stress reduction). Key components of the intervention include development of bodily awareness, managing pain, working with difficult thoughts and feelings, cultivating positive emotions and loving kindness, and relational mindfulness practices. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for group discussion and sharing. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes.
Study: NCT04831918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mueller cemented cups
Description: Patients undergo total hip arthroplasty with the implant of Mueller cemented cups
Study: NCT04981171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-thumbtack Needle Therapy
Description: Each treatment session starts with sterilizing acupoints. Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) have been selected in accordance with the principle of acupuncture prescription making and the consensus of experts on treating neck pain. Electro-thumbtack needles (0.25×2 mm) will be held by the acupuncturist between thumb and forefinger, vertically inserted into skin instantly and taped well on skin. Then assemble the gel electrodes to the surface of the conductive adhesive tape, also assemble the portable stimulation devices, adjust the current intensity from level 1 to a proper level that the participant can tolerate. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham electro-thumbtack needle therapy
Description: Each treatment session starts with sterilizing acupoints. Sham electro-thumbtack needles (0.25×0.2 mm) will be held by the acupuncturist between thumb and forefinger, taped well on skin without penetration. The adhesive tape of needles are also produced with conductive material, after assembling the gel electrodes and the portable stimulation devices, adjust the current intensity to level 1 for a minimal stimulus which will last for only 30 seconds. By this time the acupuncturist will turn the device off to cut the current. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
Study: NCT06093776

Intervention type: DEVICE
Intervention: ioveraº system
Description: the use of surgical procedure that produces lesions in peripheral nervous tissue through application of extreme cold
Study: NCT04742127

Intervention type: DIAGNOSTIC_TEST
Intervention: Single surgical debridement
Description: To describe the clinical factors associated with failure of a single surgical debridement in patients with septic arthritis of the native hip.
Study: NCT04590807

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior spinal fusion with pedicle screws
Description: Implanting pedicle screws and rods

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior vertebral body tethering
Description: Vertebral screws and cable
Study: NCT05924308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: every time 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Electroacupuncture was connected to the fixed place of Sishencong on the left and right sides of Baihui and Shenting, and the electroacupuncture instrument was returned to zero. Pull out the needle when informed patient for cotton on the above points, to make patients feel the needle was pulled out. The same treatment time of 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
Study: NCT06116864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff and GI Genius
Description: Endocuff is a polyp-detecting colonoscope attachment device. GI Genius is and Computer-Aid Detection (CADe) system to detect polyps

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GI Genius
Description: GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
Study: NCT06414473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) Extract
Description: Administered thrice daily (with food) using a sublingual route of administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered thrice daily (with food) using a sublingual route of administration
Study: NCT06155994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-MGS5
Description: intravenous administration
Study: NCT06306339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burfiralimab
Description: Humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burfiralimab
Description: Humanized monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC (Standard of care)
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC (Standard of care)
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC (Standard of care)
Description: The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for Burfiralimab (hzVSF-v13)
Study: NCT05802225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-178
Description: at an initial dose of 840 mg (1 cycle), then 420 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta
Description: at an initial dose of 840 mg (1 cycle), then 420 mg
Study: NCT04772820

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone-based coaching
Description: A telephone-based brief behavioral activation coaching program that will involve 10 sessions over 4 months. Sessions will focus on helping people to identify meaningful activities that they can safely do to decrease loneliness, increase physical activity and improve nutrition.
Study: NCT06149910

Intervention type: OTHER
Intervention: Multiple Myeloma Pathway
Description: Use and adherence to a multiple myeloma pathway.
Study: NCT06419075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: The intervention of 50 cc TXA (2 mg/mL) local infiltration is determined after carefully reviewing the literature. Scarafoni et al. recommends that the local TXA should not exceed at a concentration of 5-10 mg/mL to avoid cytotoxicity that may affect the wound re-epithelialization (22). In a prospective study on facelift bleeding, Kochuba et al. demonstrates that local TXA (1-2 mg/mL) with total 100 mg and 200 mg TXA safely and effectively decreased bleeding, operating room time, and drain output compared with traditional local anesthetic technique (14). Fathimani et all reports the local use of modified tumescent anesthesia solution with low TXA concentration (2 mg/dL) and total average dosage of TXA ranging 120-1000 mg is safe and promising in achieving less ecchymosis, edema, and seroma in common facial cosmetic surgical procedures (31). With a total dosage of 100 mg TXA and a volume of 50 cc injection, the concentration is calculated to be 2 mg/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: The intervention of 50 cc Vasopressin (0.1U/mL) local infiltration is determined from several systematic reviews. Hafidh et al. shows that injection of diluted Vasopressin (3.6 to 10 units) with various concentration during hysterectomy significantly reduces the intraoperative blood loss when compared to placebo, and without increasing the hazard of cardiovascular toxicities. Cui et al. reports similar results, but including other vaginal surgeries. The common preparation for dilute Vasopressin is 0.1 U/mL or 1.0 U/mL from a 1cc vial of 20 U/mL Vasopressin. The advantage of 0.1 U/mL concentration is to avoid a relatively large bolus of concentrated 1.0 U/mL Vasopressin injected intravascularly by accident. A cumulative total dose of 4 to 6 units of Vasopressin administered in a dilute solution is proposed to be an upper limit. Therefore, the cumulative total dose of 5 units Vasopressin from 50 cc (0.1U/mL) is in the safe therapeutic range.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: The intervention of 50 cc NaCl 0.9% local infiltration serves a placebo control.
Study: NCT05931757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: Olverembatinib will be taken 40mg qod from the time of diagnosis, and Blinatumomab will be given intravenously up to five cycles.
Study: NCT05505448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14284
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14284
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14284
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14284
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14284
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14284
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14284
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN14284
Description: Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Single ascending IV or SC administration per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Single ascending IV or SC administration per the protocol
Study: NCT06063863

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nurse led screening with Optos ultra-widefield retinal-imaging device
Description: The screening will be completed by nurse trained in using an OPTOS camera, at the same time as screening for ROP by a trained ophthalmologist using standard procedure for screening for ROP using binocular indirect ophthalmoscopy (BIO). Images taken with OPTOS will then be remotely assessed by a qualified independent opthalmologist, to see if they can diagnose and grade ROP accurately using these images
Study: NCT05157295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: 100 U of Onabotulinumtoxin A diluted in 10 mL of saline injected into the wall of the detrusor muscle at various sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: 100 U of Onabotulinumtoxin A diluted in 10 mL of saline injected into the wall of the detrusor muscle at various sites
Study: NCT06149910

Intervention type: OTHER
Intervention: Multiple Myeloma Pathway
Description: Use and adherence to a multiple myeloma pathway.

Intervention type: OTHER
Intervention: All4Cure Platform
Description: Participant in the All4Cure platform.

Intervention type: OTHER
Intervention: Documentation Pathway
Description: Use of multiple myeloma pathway through written documentation.
Study: NCT05831358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Myeloma M-Protein Analysis
Description: Participants will be screened with a blood test for monoclonal protein analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Myeloma Knowledge Questionnaires
Description: Participants will complete two questionnaires to share their attitudes toward their screening experience and completion of knowledge questions to gauge community reception and participant multiple myeloma knowledge.
Study: NCT06136429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: Device: Transcatheter Heart Valve System (Silara SR)
Study: NCT04983277

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03990896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells.
Study: NCT06444035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA35 injection
Description: HA35/B-HA injection (Registration number L20200708MP07707; Ministry of Health). The subjects can continue to take oral analgesics during the treatment period, and the comparison of the dose and interval days of the analgesics before and after the treatment can also be used as the effect judgment of the injection.
Study: NCT06002269

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary and Exercise Intervention
Description: Participants will receive food ingredients and recipes to be made and consumed for each meal, every day for a period of 3-6 weeks before surgery and 6-weeks after surgery. The menu is designed as a high protein, high calorie diet meeting targets for omega-3 fatty acids, vitamin A, and arginine (immunonutrition meal plan). In addition, participants will receive an individualized exercise prescription to be performed at home using theraband resistance bands.
Study: NCT05724407

Intervention type: OTHER
Intervention: Diagnostic assistance tool
Description: Diagnostic assistance tool for analysis of 5 prognostic and predictive markers of breast cancer (HER2, Ki67 Index, Mitoses, Estrogen Hormone Receptor, Hormone Progesteron receptors hormone of Progesteronereceptor).~Each anatomo-histopathological slide will be re-read 3 times:~* Reading 1: first reading by a pathologist in the care setting~  * Reading via the standard care procedure (microscope and physical slides)~* Reading 2: Second reading by another pathologist from the same center, as part of the research.~  * Reading via the standard procedure of care (microscope and physical slides)~* Reading 3: Third reading by the initial physician, with the algorithmic tool MoSi4BCa after digitization of the slides by a laboratory technician and after a wash-out period of 2 months.
Study: NCT05315349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete ophthalmological check-up
Description: Preoperatively, 3 to 7 days after surgery and 1 to 2 months after surgery: fundus, optical coherence tomography angiography (OCT-A)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Preoperatively and on Day 1 of surgery: 6 tubes of approximately 5 ml each, i.e. 30 ml
Study: NCT06049329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0487-0111
Description: Participants will get one tablet to swallow at the same time of the day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0487-0111)
Description: Participants will get one tablet to swallow at the same time of the day.
Study: NCT04428346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive payment
Description: Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs.